156 related articles for article (PubMed ID: 15578918)
1. The life cycle of cutaneous T cell lymphoma reveals opportunities for targeted drug therapy.
Berger CL; Edelson R
Curr Cancer Drug Targets; 2004 Nov; 4(7):609-19. PubMed ID: 15578918
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.
Berger CL; Tigelaar R; Cohen J; Mariwalla K; Trinh J; Wang N; Edelson RL
Blood; 2005 Feb; 105(4):1640-7. PubMed ID: 15514008
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
4. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells.
Berger CL; Hanlon D; Kanada D; Dhodapkar M; Lombillo V; Wang N; Christensen I; Howe G; Crouch J; El-Fishawy P; Edelson R
Blood; 2002 Apr; 99(8):2929-39. PubMed ID: 11929784
[TBL] [Abstract][Full Text] [Related]
5. Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy.
Thumann P; Lüftl M; Moc I; Bagot M; Bensussan A; Schuler G; Jenne L
Br J Dermatol; 2003 Dec; 149(6):1128-42. PubMed ID: 14674889
[TBL] [Abstract][Full Text] [Related]
6. Improved generation of anti-tumor immunity by antigen dose limitation.
Shofner JD; Vasquez JG; Berger CL; Edelson RL
J Immune Based Ther Vaccines; 2007 Feb; 5():2. PubMed ID: 17291350
[TBL] [Abstract][Full Text] [Related]
7. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
[TBL] [Abstract][Full Text] [Related]
8. Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading.
Salskov-Iversen M; Berger CL; Edelson RL
J Immune Based Ther Vaccines; 2005 Jul; 3():4. PubMed ID: 16029505
[TBL] [Abstract][Full Text] [Related]
9. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
10. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor.
Berger CL; Longley BJ; Imaeda S; Christensen I; Heald P; Edelson RL
Int J Cancer; 1998 May; 76(3):304-11. PubMed ID: 9579563
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous T-cell lymphoma: Biologic targets for therapy.
Choi J; Foss F
Curr Hematol Malig Rep; 2007 Oct; 2(4):272-7. PubMed ID: 20425380
[TBL] [Abstract][Full Text] [Related]
13. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.
Nicolay JP; Müller-Decker K; Schroeder A; Brechmann M; Möbs M; Géraud C; Assaf C; Goerdt S; Krammer PH; Gülow K
Blood; 2016 Aug; 128(6):805-15. PubMed ID: 27268084
[TBL] [Abstract][Full Text] [Related]
14. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
[TBL] [Abstract][Full Text] [Related]
15. Skin-homing CD8+ T lymphocytes show preferential growth in vitro and suppress CD4+ T-cell proliferation in patients with early stages of cutaneous T-cell lymphoma.
Thestrup-Pedersen K; Parhar R; Wu K; Bertilsson PA; Meyer B; Abu-Amero S; Hainau B; Aleisa A; Alfadley A; Hamadah I; Alajlan A; Al-Hussein K; Al-Mohanna F
Acta Derm Venereol; 2007; 87(2):118-26. PubMed ID: 17340017
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
[TBL] [Abstract][Full Text] [Related]
17. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.
Rook AH; Gelfand JM; Wysocka M; Troxel AB; Benoit B; Surber C; Elenitsas R; Buchanan MA; Leahy DS; Watanabe R; Kirsch IR; Kim EJ; Clark RA
Blood; 2015 Sep; 126(12):1452-61. PubMed ID: 26228486
[TBL] [Abstract][Full Text] [Related]
18. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
19. Reversible resistance to apoptosis in cutaneous T cell lymphoma.
Meech SJ; Edelson R; Walsh P; Norris DA; Duke RC
Ann N Y Acad Sci; 2001 Sep; 941():46-58. PubMed ID: 11594582
[TBL] [Abstract][Full Text] [Related]
20. Analysis of clonality in cutaneous T cell lymphoma and associated diseases.
Wood GS
Ann N Y Acad Sci; 2001 Sep; 941():26-30. PubMed ID: 11594579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
